Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering

Company Overview - Lucid Diagnostics Inc. is a commercial-stage cancer prevention medical diagnostics company and a subsidiary of PAVmed Inc. [4] - The company focuses on patients with gastroesophageal reflux disease (GERD), who are at risk of developing esophageal precancer and cancer [4] - Lucid's EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device are the first and only commercially available tools aimed at preventing cancer through early detection [4] Recent Financial Activity - The company announced the closing of a registered direct offering of 13,939,331 shares of common stock at a purchase price of $1.10 per share [1] - Gross proceeds from this offering are approximately $15.3 million, with around $0.8 million in placement agent's fees and other expenses [2] - Canaccord Genuity acted as the sole placement agent for this offering [2] Use of Proceeds - The net proceeds from the offering will be used for working capital and other general corporate purposes [2]